Long-Lasting Effect of Dexrazoxane Against Anthracycline Cardiotoxicity in Rats

Toxicologic Pathology

Volumn 24, Issue 4, 1996, Pages 398-402

  Torre, Paola Della ^a   Podestà, Arturo ^a   Pinciroli, Giovanni ^a   Iatropoulos, Michael J ^a   Mazué, Guy ^b  

^a Labpath Management Inc   (United States)

^b Pharmacia   (Italy)

Author keywords

ADR 529; cardioprotective agents; doxorubicin; epirubicin; ICRF 187

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; DOXORUBICIN; EPIRUBICIN; INJECTIONS, INTRAVENOUS; MALE; MONOCYTES; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE;

ANIMALIA; STAPHYLOCOCCUS PHAGE 187;

EID: 0029790879     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339602400402     Document Type: Article

References (29)

1. Bienvenu P., Caron L., Gasparutto D., and Kergonou JF (1992). Assessing and counteracting the prooxidant effects of anticancer drugs. In: Free Radicals and Aging, I Emerit and B Chance (eds). Birkhauser Verlag, Basel, pp. 257–262.
2. Chacon E. and Acosta D. (1991). Mitochondrial regulation of superoxide by Ca2+: An alternate mechanism for the cardiotoxicity of doxorubicin. Toxicol. Appl. Pharmacol. 107: 117-128.
3. Danesi R., Bernardini N., Macchiarini P., and Del Tacca M. (1990). Doxorubicin cardiotoxicity is reduced by pretreatment with the iron chelator ADR-529. Eur. J. Pharmacol. 183: 1703.
4. Davies KJA and Doroshow JH (1986). Redox cycling of anthracyclines by cardiac mitochondria. J. Biol. Chem. 261: 3060-3067.
5. Demant EJF and Jensen PK (1983). Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur. J. Biochem. 132: 551-556.
6. Dunn OJ (1964). Multiple comparison using rank sums. Technometries 3: 241.
7. Earm YE, Ho WK, and So I. (1994). Effects of adriamycin on ionic currents in single cardiac myocytes of the rabbit. J. Mol. Cell. Cardiol. 26: 163-172.
8. Fenoglio JJ (1983). The effects of drugs on the cardiovascular system. In: Cardiovascular Pathology, Vol. 2, MD Silver (ed). Churchill Livingstone, New York, pp. 1085–1107.
9. Flandina C., Sanguedolce R., Rausa L., and D'Alessandro N. (1990). Ameliorative effects of ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res. Comm. Chem. Pathol. Pharmacol. 70: 259-272.
10. Frank L. (1991). Oxidant injury to pulmonary endothelium. In: The Pulmonary Circulation and Acute Lung Injury, 2nd ed., SI Said (ed). Futura Publishing Co., Mount Kisco, NY, pp. 403–432.
11. Gianni L., Corden BJ, and Myers CE (1983). The biochemical basis of anthracycline toxicity and antitumor activity. Rev. Biochem. Toxicol. 5: 1-82.
12. Gutteridge JM (1984). Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III) complex. Biochem. Pharmacol. 33: 1725-1728.
13. Hasinoff BB (1994). Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane. J. Pharmaceut. Sci. 83: 64-67.
14. Herman EH, Ardalan B., Bier C., Waravdekar V., and Krop S. (1981). Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters. Cancer Treat. Rep. 63: 89-92.
15. Herman EH and Ferrans VJ (1981). Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+)-1,2-bis(3,5-diopiperazinyl-1-yl)propane (ICRF-187). Cancer Res. 41: 3436-3440.
16. Herman EH and Ferrans VJ (1983). Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab. Invest. 49: 69-77.
17. Herman EH and Ferrans VJ (1990). Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treat. Rev. 17: 155-160.
18. Herman EH, Ferrans VJ, Young RS, and Hamlin RL (1988). Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs. Cancer Res. 48: 6918-6925.
19. latropoulos MJ (1993). Comparative histokinetic and xenodynamic considerations in toxicity. In: Drug Toxicokinetics, PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York, pp. 245–266.
20. Monti E. and Sinha BK (1990). Potentiation of doxorubicin cytotoxicity by (+)-1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF-187) in human leukemic HL-60 cells. Cancer Comm. 2: 145-149.
21. Perkins WE, Schroeder RL, Carrano RA, and Imondi AR (1982). Effect of ICRF-187 on doxorubicin-induced myocardial effects ir the mouse and guinea pig. Br. J. Cancer 46: 662-667.
22. Podestà A., Della Torre P., Pinciroli G., Iatropoulos MJ, Brughera M. and Mazué G. (1994). Evaluation of 4’-iodo-4’-deoxydoxorubicininduced cardiotoxicity in two experimental rat models. Toxicol Pathol. 22: 68-71.
23. Rajagopalan S., Politi PM, and Sinha BK (1988). Adriamycin-in duced free radical formation in the perfused rat heart: Implications for cardiotoxicity. Cancer Res. 48: 4766-4769.
24. Robert J. (1993). Epirubicin. Drugs 45(suppl.2): 20-30.
25. Siegel S. (1956). Nonparametric Statistics for the Behavioral Sciences. McGraw-Hill, New York. 184 pp.
26. Solcia E., Ballerini L., Bellini O., Magrini U., Bertazzoli C., Tosana G., Sala L., Balconi F., and Rallo F. (1981). Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 67: 461-472.
27. Solem LE, Henry TR, and Wallace KB (1994). Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129: 214-222.
28. Villani F., Galimberti M., Monti E., Cova D., Lanza E., Rozza-Dionigi A., Favalli L., and Poggi P. (1990). Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Toxicol. Appl. Pharmacol. 102: 292-299.
29. Wadler S., Green MD, and Muggia FM (1986). Synergistic activity of doxorubicin and the bisdioxopiperazine(+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ICRF-187) against the murine sarcoma S180. Cancer Res. 46: 1176-1181.